GlassScriptPhysician profile
Biju Marath
NPI 1629234463
$3,089.73
in general payments reported to CMS, 2019-2025
29 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $213 · 2021: $52.12 · 2022: $329 · 2023: $441 · 2024: $913 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,799 · Education: $27.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.32 |
| Education | $27.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $368.50 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $360.95 | 2020-2025 | Terlivaz, Acthar |
| Amgen INC. | $325.31 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Opko Pharmaceuticals, LLC | $299.34 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $280.25 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $229.73 | 2019-2024 | Velphoro |
| Vifor Pharma, INC. | $204.57 | 2019-2024 | Veltassa |
| Novartis Pharmaceuticals Corporation | $169.97 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.80 | 2021-2024 | |
| Akebia Therapeutics INC | $117.11 | 2019-2024 | Vafseo, Auryxia |
| Novo Nordisk INC | $76.56 | 2025 | Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $61.73 | 2022-2024 | |
| Mallinckrodt Enterprises LLC | $55.97 | 2019 | |
| Aurinia Pharma U.S., INC. | $51.94 | 2024 | Lupkynis |
| Cormedix INC. | $41.85 | 2024 | Defencath |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $41.53 | 2019 | |
| Daiichi Sankyo INC. | $40.56 | 2019-2020 | |
| Renalytix Ai, INC. | $33.59 | 2022-2023 | Kidneyintelx Blood Collection Convenience Kit |
| Ani Pharmaceuticals, INC. | $27.63 | 2025 | Purified Cortrophin Gel |
| Medtronic, INC. | $26.62 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.98 | 2025 | |
| Pharmacosmos Therapeutics INC. | $22.74 | 2022 | |
| Scpharmaceuticals INC. | $19.20 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.50 | 2023 | Givlaari |
| Boston Scientific Corporation | $18.15 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.61 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $15.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.56 | 2020 | |
| Travere Therapeutics, INC. | $3.32 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biju Marath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.